Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

BACKGROUND: Isatuximab (Isa), an anti‐CD38 monoclonal antibody, and carfilzomib (K), a next‐generation proteasome inhibitor (PI), both have potent single‐agent activity in relapsed and refractory multiple myeloma (RRMM). METHODS: This phase 1b study evaluated the combination of Isa and K in 33 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Thomas G., Shah, Nina, Richter, Joshua, Vesole, David H., Wong, Sandy W., Huang, Chiung‐Yu, Madduri, Deepu, Jagannath, Sundar, Siegel, David S., Biran, Noa, Wolf, Jeffrey L., Parekh, Samir, Cho, Hearn J., Munster, Pamela, Richard, Shambavi, Ziti‐Ljajic, Samira, Chari, Ajai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252002/
https://www.ncbi.nlm.nih.gov/pubmed/33735504
http://dx.doi.org/10.1002/cncr.33448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252002/
https://www.ncbi.nlm.nih.gov/pubmed/33735504
http://dx.doi.org/10.1002/cncr.33448

Ejemplares similares